N-Methyl-4-[2-(1-pyrrolidinyl)ethoxy]aniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-Methyl-4-[2-(1-pyrrolidinyl)ethoxy]aniline
• 英文别名: N-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]aniline；N-methyl-4-(2-pyrrolidin-1-ylethoxy)aniline
• 化学式: C₁₃H₂₀N₂O
• mdl: MFCD11891823
• 分子量: 220.315
• InChiKey: ZMDDOSWQDIJCRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  THF-Hex-Et3N 、 N-苯基甲酰胺 生成 N-Methyl-4-[2-(1-pyrrolidinyl)ethoxy]aniline
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES
  申请人：Hoffmann Matthias

  公开号：US20110201608A1

  公开（公告）日：2011-08-18

  The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R 1 denotes a group A selected from among —O—R 3 , —NR 3 R 4 , —CR 3 R 4 R 5 , -(ethyne)-R 3 , —S—R 3 , —SO—R 3 and SO 2 —R 3 or R 1 denotes a group B selected from among C 6-10 -aryl, five- to ten-membered, mono- or bicyclic heteroaryl with 1-3 heteroatoms selected independently of one another from among N, O and S; while this heteroaryl is linked to the structure according to formula 1 via either a C atom or an N atom, three- to ten-membered, mono- or bicyclic, saturated or partially saturated heterocyclic group with 1-3 heteroatoms selected independently of one another from among N, O and S, while this heterocyclic group is linked to the structure according to formula 1 via either a C atom or an N atom, and 5- to 11-membered spiro group which may optionally contain 1, 2 or 3 heteroatoms selected independently of one another from among N, O and S, while this spiro group is linked to the structure according to formula 1 via either a C atom or an N atom, while this group B may optionally be substituted as described in claim 1 and wherein R 2 is and R 3 , R 4 , R 5 , R 6 , R 6′ , R 7 , R 8 , R 9 , R 10 , V, n and m may have the meanings given in claim 1 , as well as pharmaceutical compositions containing these compounds.

  该发明涉及公式1的新取代萘啉类化合物，以及其药理学上可接受的盐、对映体、对映异构体、外消旋体、水合物或溶剂合物，其中R1表示从以下选取的A基团，包括—O—R3、—NR3R4、—CR3R4R5、-(乙炔)-R3、—S—R3、—SO—R3和SO2—R3，或R1表示从以下选取的B基团，包括C6-10-芳基、含有1-3个异原子（N、O和S）的五至十元杂环芳基，而此杂环芳基通过碳原子或氮原子与公式1中的结构连接，含有1-3个异原子（N、O和S）的三至十元杂环饱和或部分饱和环族基团，而此杂环基团通过碳原子或氮原子与公式1中的结构连接，以及可能含有1、2或3个异原子（N、O和S）的五至十一元螺环基团，而此螺环基团通过碳原子或氮原子与公式1中的结构连接，其中该B基团可以选择地按照权利要求1中所述进行取代，R2为，R3、R4、R5、R6、R6′、R7、R8、R9、R10、V、n和m的含义如权利要求1中所述，以及含有这些化合物的药物组合物。
• [EN] TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY<br/>[FR] DÉRIVÉS TRIAZOLES À ACTIVITÉ ANTIFONGIQUE
  申请人：KING S COLLEGE LONDON

  公开号：WO2021156636A1

  公开（公告）日：2021-08-12

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, Q2, L1 and n are as defined herein. The compounds have antifungal properties and are useful in the treatment of fungal infections, including infections that are resistant to conventions anti-fungal agents. Q1 is selected from: (Formulae Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij and Ik) wherein * indicates the point of attachment to L1.

  揭示了公式(I)的化合物及其药学上可接受的盐，其中R1、R2、Q2、L1和n的定义如本文所述。这些化合物具有抗真菌性能，并可用于治疗真菌感染，包括对传统抗真菌药物产生耐药性的感染。Q1选自:(公式Ia、Ib、Ic、Id、Ie、If、Ig、Ih、Ii、Ij和Ik)，其中*表示与L1的连接点。
• Benzothiophene compounds as antithrombotic agents and intermediates
  申请人：ELI LILLY AND COMPANY

  公开号：EP0997460A1

  公开（公告）日：2000-05-03

  This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors. wherein E is CRe or N in which Re is hydrogen, methyl, methoxy or halo; R1 is hydrogen or methyl; R2 is R2a or R2b in which R2a is -X2-(CH2)n-Rf in which X2 is a direct bond, methylene or O; n is 1, 2 or 3; and Rf is 5-tetrazolyl, carboxy, [(1-4C)alkoxy]carbonyl or hydroxymethyl; R2b is -X2-(CH2)m-NRaRb in which X2 is a direct bond, methylene or O; m is 1, 2 or 3; provided that when m is 1, then X2 is a direct bond; and Ra and Rb are independently hydrogen or (1-3C)alkyl or the group NRaRb is pyrrolidino, piperidino or morpholino; R3 is -X3-(CH2)s-NRsRt in which X3 is a direct bond, methylene or O; s is 1 or 2; provided that when s is 1, then X3 is a direct bond; and Rs and Rt are independently hydrogen or (1-3C)alkyl or the group NRsRt is pyrrolidino, piperidino or morpholino; and R6 is hydrogen, hydroxy or methoxy.

  本申请涉及本文定义的新型式 I 化合物（及其药学上可接受的盐）、其制备工艺和中间体、包含新型式 I 化合物的药物制剂，以及式 I 化合物作为凝血酶抑制剂的用途。 其中 E 是 CRe 或 N，其中 Re 是氢、甲基、甲氧基或卤素； R1 是氢或甲基 R2 是 R2a 或 R2b，其中 R2a 是-X2-(CH2)n-Rf，其中 X2 是直接键、亚甲基或 O；n 是 1、2 或 3；Rf 是 5-四唑基、羧基、[(1-4C)烷氧基]羰基或羟甲基； R2b 是-X2-( )m-NRaRb，其中 X2 是直接键、亚甲基或 O；m 是 1、2 或 3；但当 m 是 1 时，X2 是直接键；Ra 和 Rb 独立地是氢或 (1-3C)烷基或基团 NRaRb 是吡咯烷基、哌啶基或吗啉基； R3 是-X3-( )s-NRsRt，其中 X3 是直接键、亚甲基或 O；s 是 1 或 2；条件是当 s 为 1 时，X3 是直接键；Rs 和 Rt 独立地是氢或 (1-3C)烷基或基团 NRsRt 是吡咯烷基、哌啶基或吗啉基；以及 R6 是氢、羟基或甲氧基。
• US6133262A
  申请人：——

  公开号：US6133262A

  公开（公告）日：2000-10-17